Matinas BioPharma Holdings, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
1545 ROUTE 206 SOUTH, BEDMINSTER, NJ, 07921
Mailing Address
1545 ROUTE 206 SOUTH, BEDMINSTER, NJ, 07921
Phone
908-484-8805
Fiscal Year End
1231
EIN
463011414
Financial Overview
FY2025
$7.21M
Total Assets
$5.05M
Total Liabilities
$7.28M
Cash & Equivalents
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | March 31, 2026 | View on SEC |
| 8-K Current report of material events | January 23, 2026 | View on SEC |
| 8-K Current report of material events | December 12, 2025 | View on SEC |
| 8-K Current report of material events | November 21, 2025 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | November 14, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 10, 2025 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | September 25, 2025 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | August 19, 2025 | View on SEC |
| 8-K Current report of material events | August 18, 2025 | View on SEC |
| 10-Q Quarterly financial report | August 14, 2025 | View on SEC |
Annual Reports
10-K
March 31, 2026
- Clinical-stage biotech focused on proprietary lipid nanocrystal (LNC) drug delivery technology.
- Actively seeking a buyer, merger partner, or intellectual property licensing deal.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.